Showing results (151-160 of 212) with videos related to

Sort By:
Pageof 22
British Journal of Cancer|January 24, 2018
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Genome Medicine|February 4, 2014
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinomaLisa Evers, Pedro A Perez-Mancera, Elizabeth Lenkiewicz, et al.
British Journal of Cancer|September 27, 2017
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumoursJeffrey R Infante, Ronald L Korn, Lee S Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignanciesMiguel A Villalona-Calero, S Gail Eckhardt, Geoffrey Weiss, et al.
Investigational New Drugs|December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignanciesGlen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Cancer Research|February 27, 2009
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancerChristopher J Riley, Kevin P Engelhardt, Jose W Saldanha, et al.
British Journal of Cancer|July 20, 2017
Clinical study of genomic drivers in pancreatic ductal adenocarcinomaMichael T Barrett, Ray Deiotte, Elizabeth Lenkiewicz, et al.
The New England Journal of Medicine|September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449Charles M Rudin, Christine L Hann, John Laterra, et al.
Genome Medicine|September 29, 2020
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesionsWei Lin, Pawan Noel, Erkut H Borazanci, et al.
British Journal of Cancer|March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysisUwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
Pageof 22